B型利钠肽和N末端B型利钠肽原——在稳定型冠状动脉疾病中的诊断作用
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease.
作者信息
Weber Michael, Mitrovic Veselin, Hamm Christian
机构信息
Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany.
出版信息
Exp Clin Cardiol. 2006 Summer;11(2):99-101.
Abstract
B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia. Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure. Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated. For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome. However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.
摘要
B型利钠肽（BNP）及其N端片段（NT-proBNP）是心室心肌细胞在心室壁压力增加和心肌缺血时释放的。BNP和NT-proBNP已被证明是心力衰竭患者可靠的诊断和预后生物标志物。最近，BNP和NT-proBNP在冠状动脉疾病（CAD）患者中的诊断作用已得到研究。对于急性冠状动脉综合征患者，已有大量研究数据，而对于稳定型CAD患者，近期仅有有限的数据；尽管数据有限，但这些数据表明BNP和NT-proBNP水平升高与CAD的严重程度相关，从而为不良临床结局提供预后信息。然而，临床和治疗意义尚不清楚，需要进一步研究阐明。
相似文献
1
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease.
Exp Clin Cardiol. 2006 Summer;11(2):99-101.
2
3
The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
Intern Med. 2018 Sep 15;57(18):2621-2630. doi: 10.2169/internalmedicine.0471-17. Epub 2018 Apr 27.
4
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
J Am Coll Cardiol. 2007 Jul 17;50(3):205-14. doi: 10.1016/j.jacc.2007.03.038. Epub 2007 Jun 29.
5
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
J Am Heart Assoc. 2017 May 29;6(6):e004743. doi: 10.1161/JAHA.116.004743.
6
Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease.
Circ J. 2007 Apr;71(4):499-505. doi: 10.1253/circj.71.499.
7
N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris.
Am Heart J. 2004 Oct;148(4):612-20. doi: 10.1016/j.ahj.2004.04.021.
8
N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.
Am J Cardiol. 2006 May 15;97(10):1530-4. doi: 10.1016/j.amjcard.2005.11.090. Epub 2006 Mar 31.
9
Stress-delta B-type Natriuretic Peptide Levels as a Test for Inducible Myocardial Ischemia: A Systematic Review and Meta-Analysis.
Cureus. 2020 Mar 2;12(3):e7165. doi: 10.7759/cureus.7165.
10
N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease.
Clin Res Cardiol. 2007 Apr;96(4):218-26. doi: 10.1007/s00392-007-0491-2. Epub 2007 Feb 26.
引用本文的文献
1
Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial.
J Gerontol A Biol Sci Med Sci. 2025 May 5;80(6). doi: 10.1093/gerona/glaf005.
2
Blood component-associated acute transfusion reactions in pediatric patients: experience of a tertiary care hospital.
Turk J Med Sci. 2024 Jul 16;54(5):924-929. doi: 10.55730/1300-0144.5869. eCollection 2024.
3
Early identification of severe immune checkpoint inhibitor associated myocarditis: From an electrocardiographic perspective.
Cancer Med. 2024 Aug;13(15):e7460. doi: 10.1002/cam4.7460.
4
Membrane-Free Lateral Flow Assay with the Active Control of Fluid Transport for Ultrasensitive Cardiac Biomarker Detection.
Anal Chem. 2024 May 7;96(18):7014-7021. doi: 10.1021/acs.analchem.4c00142. Epub 2024 Apr 24.
5
Brain natriuretic peptide as a clinical screening tool for the diagnosis of Kawasaki disease.
Medicine (Baltimore). 2023 Jul 21;102(29):e34319. doi: 10.1097/MD.0000000000034319.
6
Association of Brain Natriuretic Peptide Levels at Time of Injury with Morbidity and Mortality in Patients with Surgically Treated Hip Fractures.
JB JS Open Access. 2023 Apr 4;8(2). doi: 10.2106/JBJS.OA.22.00102. eCollection 2023 Apr-Jun.
7
Serum Copeptin in Cardiooncology Practice: Review of Pathophysiological and Clinical Implications.
Balkan Med J. 2023 Mar 8;40(2):82-92. doi: 10.4274/balkanmedj.galenos.2023.2023-2-14.
8
VDR Regulates BNP Promoting Neurite Growth and Survival of Cochlear Spiral Ganglion Neurons through cGMP-PKG Signaling Pathway.
Cells. 2022 Nov 23;11(23):3746. doi: 10.3390/cells11233746.
9
Diversified Shifts in the Cross Talk between Members of the Gut Microbiota and Development of Coronary Artery Diseases.
Microbiol Spectr. 2022 Dec 21;10(6):e0280422. doi: 10.1128/spectrum.02804-22. Epub 2022 Oct 27.
10
Ultrasensitive and Rapid Detection of N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Using Fiber Optic Nanogold-Linked Immunosorbent Assay.
Biosensors (Basel). 2022 Sep 9;12(9):746. doi: 10.3390/bios12090746.
本文引用的文献
1
Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina.
Circulation. 2005 Oct 4;112(14):2102-7. doi: 10.1161/CIRCULATIONAHA.105.550715. Epub 2005 Sep 26.
2
Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure.
Heart. 2005 May;91(5):606-12. doi: 10.1136/hrt.2004.037762.
3
4
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
N Engl J Med. 2005 Feb 17;352(7):666-75. doi: 10.1056/NEJMoa042330.
5
B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease.
Am J Cardiol. 2005 Jan 1;95(1):24-8. doi: 10.1016/j.amjcard.2004.08.058.
6
Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study.
Eur Heart J. 2005 Feb;26(3):241-9. doi: 10.1093/eurheartj/ehi036. Epub 2004 Nov 30.
7
Acute myocardial hypoxia increases BNP gene expression.
FASEB J. 2004 Dec;18(15):1928-30. doi: 10.1096/fj.03-1336fje. Epub 2004 Sep 22.
8
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.
J Am Coll Cardiol. 2004 Nov 16;44(10):1988-95. doi: 10.1016/j.jacc.2004.07.057.
9
Detection of exercise-induced ischemia by changes in B-type natriuretic peptides.
J Am Coll Cardiol. 2004 Nov 16;44(10):1980-7. doi: 10.1016/j.jacc.2004.08.045.
10
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Circulation. 2004 Nov 16;110(20):3206-12. doi: 10.1161/01.CIR.0000147611.92021.2B. Epub 2004 Nov 8.
Zotero 插件